Celvapan (influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated))
- Region
- 🇪🇺 EU
- Active substance
- influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated)
- Company
- Nanotherapeutics Bohumil, s.r.o.
- Status
- Withdrawn
- Therapeutic area
- Disease Outbreaks; Influenza, Human; Immunization
- EU approval
- Wed 04 Mar 2009
- Application
- EMEA/H/C/000982
- ATC
- J07BB01
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza caused by A(H1N1)v 2009 virus. Celvapan should be used in accordance with official guidance.
Regulatory milestones
No milestones recorded in the last year.
Follow Celvapan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.